TARCEVA COMBINATION APPROVED TO TREAT PANCREATIC CANCER

OSI Pharmaceuticals and Genentech have received FDA approval for Tarceva (erlotinib) in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva is a once-daily oral tablet already approved for use in patients with non-small cell lung cancer whose disease has progressed after one or more courses of chemotherapy.